•  
  •  
 

Abstract

BACKGROUND: Programmed death ligand 1 is tumor marker which is anti apoptotic factor (PD-L1, B7-H1, and CD274) and is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. THE AIMS OF STUDY : To investigate the expression of Programmed death ligand 1 (PD-L1, B7-H1, CD274) in prostate cancer, benign prostatic hyperplasia, and normal prostatic tissue using anti-PD-L1 antibody; and to correlate the result of study with some clinico-pathological parameters such as the age of                       the patients and grade of tumor. PATIENTS AND METHODS: A retrospective case control study, included 90 cases was divided into three groups include 30 cases of Prostate cancer; 30 cases of benign prostate hyperplasia and 30 cases of normal prostatic tissue. RESULTS: Programmed death ligand 1was expressed in 10% of Prostate cancer cases and there is no expression in benign Prostatic hyperplasia and normal prostatic tissue. In Programmed death ligand1positive cases there is a significant correlation with age of patients, high Gleason score. CONCLUSION: Immunohistochemically, it is concluded that the expression of Programmed death ligand                           1 increases as the age of the patient increases, high Gleason score and there is no expression of Programmed death ligand 1in benign prostate hyperplasia and normal control tissue.  

DOI

10.52573/ipmj.2023.179185

Download

Share

COinS